Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 9/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.39 |
| ▸ | ABCG2 | Q9UNQ0 | 5/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
| ▸ | FUBP1 | Q96AE4 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL954341 | 0.87 | ABCB1 (0.43) | ABCB1ADORA2AABCG2ADORA1ADORA2B | |
| SCHEMBL30515692 | 0.83 | CXCR2 (0.49) | ABCB1ADORA2AABCG2ADORA1ADORA2B | |
| SCHEMBL954898 | 0.83 | CXCR2 (0.49) | ABCB1ADORA2AABCG2ADORA1ADORA2B | |
| SCHEMBL959394 | 0.80 | ABCB1 (0.44) | ABCB1ADORA2AABCG2ADORA1ADORA2B | |
| SCHEMBL956506 | 0.77 | ABCB1 (0.44) | ABCB1ADORA2AABCG2ADORA1ADORA2B | |
| SCHEMBL956084 | 0.76 | CXCR2 (0.37) | — | |
| SCHEMBL959357 | 0.74 | DPP4 (0.41) | ABCB1ADORA2AABCG2ADORA1ADORA2B | |
| SCHEMBL3341610 | 0.73 | KDM4E (0.41) | ABCB1ADORA2AABCG2ADORA1ADORA2B | |
| SCHEMBL956372 | 0.72 | FUBP1 (0.39) | ABCB1ABCG2DPP4METFUBP1 | |
| SCHEMBL956593 | 0.72 | DPP4 (0.41) | ABCB1ABCG2DPP4METFUBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009429-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF CXCR2 | NOVARTIS AG (CH) | 2011-01-13 | — | — | US | disclosed |
| EP-2257552-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF CXCR2 | Novartis AG (CH) | 2010-12-08 | — | — | EP | disclosed |
| WO-2009106539-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF CXCR2 | NOVARTIS AG (CH) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009429-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF CXCR2 | CXCR2, CXCR1, CXCR3 | ABCB1 649/4885ADORA2A 279/4885ABCG2 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.